Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Academy, adjuvant, Anstalt, Axe, backlog, batch, Baxter, Benjamin, blocker, Boondock, breach, British, cast, CDRB, Century, CEO, chart, Chinese, chloride, Columbia, Companny, Conn, contact, Corn, creation, drew, Emprise, Entertainment, exceeding, explore, FCMA, Feeln, Fellow, Film, floor, Fondinvest, formula, Fox, Fried, fusion, Gamble, GlaxoSmithKline, Godzilla, Grace, GSK, Hallmark, Healthspan, heavy, Ideation, IDI, illustrate, Immune, Imputation, inflation, interpolating, Jeff, Jeremy, King, Lentiviral, linearly, MabVax, Maple, Married, matching, metric, modified, motion, multiplying, Murderer, Nonoperating, nonrenewable, outsourced, panel, pharma, picture, pivotal, played, Procter, profile, protocol, Purple, ready, Rebel, reclassifying, redacted, redeemed, repaid, resale, resell, residual, resource, Rob, Robert, Rudy, SAS, Savoy, seal, shelf, Silver, slight, SmallCap, SPA, SROne, strong, subtracting, sudden, Suntava, SVP, TLR, Twentieth, unanimously, unaudited, unchanged, Unilever, vaccine, Valley, Valor, VBI, vector, verification, Verified, verify, video
Removed:
AMEX, anticancer, assisted, bacteria, banker, billboard, biopharmaceutical, Castle, catalog, CDSI, cell, choice, cholesterol, clearing, Coif, cover, developer, discovery, engineered, eventually, executing, Farm, genetically, graduated, inception, Intellect, Ivax, IVC, IVD, mail, marketable, McGladrey, merchant, niacin, OMMH, Omnimmune, owner, pain, pecuniary, Pluristem, positioning, possessing, practicing, premium, PSTI, ROX, SCLL, SearchMedia, seeking, semantic, Sorrento, Stem, television, Transworld, twenty, Winston, WPHM
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Form of Stock Certificate Representing Shares of Chromadex Corporation Common Stock
- 10.44 Joint Development Agreement
- 23.1 Consent of Marcum, LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of the Chief Executive Officer Pursuant to ?240.13A-14 or ?240.15D-14 of the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of the Chief Financial Officer Pursuant to ?240.13A-14 or ?240.15D-14 of the Securities Exchange Act of 1934, As Amended
- 32.1 Certification Pursuant to 18 U.s.c. Section 1350 (As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002)
- Download Excel data file
- View Excel data file
CDXC similar filings
Filing view
External links
Exhibit 32.1
Certification Pursuant to 18 U.S.C. Section 1350
(as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)
In connection with this annual report of ChromaDex Corporation (the “Company”) on Form 10−K for the year ending January 2, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Frank L. Jaksch Jr., Chief Executive Officer of the Company, and Thomas C. Varvaro, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002, that, to our knowledge:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: March 17, 2016
/s/ FRANK L. JAKSCH JR.
Frank L. Jaksch Jr.
Chief Executive Officer
(Principal Executive Officer)
/s/ THOMAS C. VARVARO
Thomas C. Varvaro
Chief Financial Officer
(Principal Accounting Officer)